ArticleRMD open2026

Anlotinib ameliorates myositis-associated interstitial lung disease (MAILD) via suppression of the NETs-PI3K/Akt-driven epithelial-mesenchymal transition.

Jumei Yang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.